I think the answer that MSB seem to give in the webinar was that they were only going for conditional approval and then trials. So we will see if they stick with that and refuse to do a adult trial unless they are given conditional on children. Makes sense, as we shouldn't need to demonstrate efficacy/potency in adults, when there's data for children available.
MSB to dispute FDA finding in Type A meeting, page-253
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
0.105(7.64%) |
Mkt cap ! $1.689B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.49 | $1.38 | $8.181M | 5.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25443 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 60811 | 4 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |